A Study of HB0025 Injection in Patients With Advanced Renal Cancer
Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).